Literature DB >> 8261457

Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.

Y Ichikawa1, M Nishida, H Suzuki, S Yoshida, H Tsunoda, T Kubo, K Uchida, M Miwa.   

Abstract

A series of 57 mucinous and 47 serous ovarian tumors (adenomas, tumors of borderline malignancy, and carcinomas) were examined by polymerase chain reaction-single strand conformation polymorphism analysis and direct sequencing for mutations in codons 12, 13, and 61 of K-ras gene. Higher incidence of K-ras mutations was observed in mucinous tumors compared to serous ones. Mutations were detected in 4 of 30 mucinous adenomas (13%), in 4 of 12 mucinous tumors of borderline malignancy (33%), and in 7 of 15 mucinous carcinomas (46%). Only 1 of 17 serous carcinomas (6%) had a mutation of K-ras in serous ovarian tumors. All mutations identified were in codon 12. Detailed analysis revealed that more K-ras mutations in mucinous adenomas were observed in intestinal type (identified in 4 of 13) than in endocervical type (identified in 0 of 17). Thus, K-ras gene codon 12 mutations in mucinous ovarian adenomas appear to be associated with the occurrence of intestinal type adenomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8261457

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian carcinomas.

Authors:  R Wu; D C Connolly; X Ren; E R Fearon; K R Cho
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

Review 2.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

3.  FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.

Authors:  Filippo Pietrantonio; Claudia Maggi; Giuseppe Fanetti; Roberto Iacovelli; Maria Di Bartolomeo; Francesca Ricchini; Marcello Deraco; Federica Perrone; Dario Baratti; Shigeki Kusamura; Elena Tamborini; Alessandra Castano; Paola Valentina Consonni; Ilaria Bossi; Cecilia Gavazzi; Massimo Milione; Giuseppe Pelosi; Filippo de Braud
Journal:  Oncologist       Date:  2014-06-20

4.  Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas.

Authors:  Akira Kanoh; Akira Seko; Hiroko Ideo; Midori Yoshida; Mitsuharu Nomoto; Suguru Yonezawa; Masaru Sakamoto; Reiji Kannagi; Katsuko Yamashita
Journal:  Glycoconj J       Date:  2006-07       Impact factor: 2.916

5.  Stanniocalcin 1 and ovarian tumorigenesis.

Authors:  Guangzhi Liu; Gong Yang; Bin Chang; Imelda Mercado-Uribe; Miao Huang; Jingfang Zheng; Robert C Bast; Sue-Hwa Lin; Jinsong Liu
Journal:  J Natl Cancer Inst       Date:  2010-05-18       Impact factor: 13.506

6.  Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.

Authors:  Hyeyeung Kim; Rong Wu; Kathleen R Cho; Dafydd G Thomas; Gabrielle Gossner; J Rebecca Liu; Thomas J Giordano; Kerby A Shedden; David E Misek; David M Lubman
Journal:  Proteomics Clin Appl       Date:  2008-03-07       Impact factor: 3.494

7.  Long Non-coding RNA LINC01420 Contributes to Pancreatic Cancer Progression Through Targeting KRAS Proto-oncogene.

Authors:  Hongjun Zhai; Xinwu Zhang; Xiaoli Sun; Di Zhang; Shuangyu Ma
Journal:  Dig Dis Sci       Date:  2019-09-27       Impact factor: 3.199

Review 8.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs.

Authors:  E Tsuchiya; R Furuta; N Wada; K Nakagawa; Y Ishikawa; B Kawabuchi; Y Nakamura; H Sugano
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Reproductive characteristics in relation to ovarian cancer risk by histologic pathways.

Authors:  M A Merritt; M De Pari; A F Vitonis; L J Titus; D W Cramer; K L Terry
Journal:  Hum Reprod       Date:  2013-01-12       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.